Medtech innovator Robeauté has raised USD 28 million in a funding round led by Plural, Cherry Ventures, and Kindred Ventures. Other participants included LocalGlobe, Think.Health, APEX Ventures, and strategic partner Brainlab. The fresh capital will support the development of Robeauté’s groundbreaking microrobot technology, with plans to initiate human trials in 2026 and establish a presence in the US as the company works toward FDA approval.
Neurological disorders remain challenging to diagnose and treat, particularly in their early stages when intervention is most effective. Current neurosurgical techniques rely on rigid tools and linear pathways, which limit precision and multi-site access. Additionally, drug treatments often struggle to overcome the blood-brain barrier to reach targeted areas.
Robeauté’s microrobots, roughly the size of a grain of rice, are designed to navigate curved routes within the brain’s extracellular matrix. These modular devices can safely access multiple sites and perform localized tasks, such as delivering molecules, implanting electrodes, and collecting live data or cell samples. By enabling highly targeted interventions, this technology aims to revolutionize the treatment of neuropathologies and deepen our understanding of brain disorders.
Founded by robotics expert Bertrand Duplat and operations specialist Joana Cartocci, Robeauté was inspired by a personal experience when Duplat’s mother was diagnosed with glioblastoma. Duplat, who previously worked with McGill University and the European Space Agency, brings decades of experience in developing robotic systems for extreme environments. Together, the founders have guided the company in securing over 50 patents, crafting the microrobot’s intricate components, including an engine, propeller, steering mechanism, and tracking system. These features enable real-time monitoring of the microrobot’s movements during procedures.
The technology is undergoing animal trials, focusing on its potential as an advanced biopsy tool. Future applications include treatment delivery and real-time monitoring, achieved through collaborations with research institutions and industrial partners.
Brainlab’s strategic investment reflects its commitment to advancing neurology and reshaping neurosurgical approaches. This partnership will support Robeauté’s expansion into the US market, where the company plans to seek regulatory approval before targeting European markets.
Robeauté’s leadership highlights the transformative potential of their innovation. “Microrobots represent an unexplored frontier in medicine,” said Bertrand Duplat, CEO of Robeauté. “Our technology offers unprecedented access to the brain, enabling precision medicine that can transform patient outcomes. This funding will help us advance our mission to equip neurosurgeons with cutting-edge tools to make a difference.”
Co-founder and COO Joana Cartocci echoed the sentiment, emphasizing the paradigm shift their technology could bring. “Our microrobot functions like a brain gardener, tending to affected areas with adaptable extensions for various applications. Starting with advanced biopsies, the possibilities are endless as we unlock safe access and site-specific data.”
Investors expressed confidence in Robeauté’s impact. Ian Hogarth of Plural remarked, “Robeauté’s microrobots could revolutionize brain treatment, much like the endoscope transformed gastrointestinal medicine.” Filip Dames of Cherry Ventures added, “The team is at the forefront of robotics, AI, and medicine, paving the way for transformative care for neurodegenerative diseases.”
With its innovative approach, Robeauté is poised to redefine neurosurgery and improve outcomes for patients worldwide.
